NDRG1 overexpression has also been shown to inhibit the downstream targets of EGFR signaling, e.g., MEK1/2 or ERK1/2, in pancreatic and prostate carcinoma cells (Dixon et al., 2013; Kovacevic et al., 2013, 2016). This evidence concerns the gene MAP2K1 and prostate carcinoma.